# A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection

> **NCT05801835** · NA · UNKNOWN · sponsor: **CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** (cytarabine: daunorubicin) liposome for injection
- **DRUG:** Vyxeos
- **DRUG:** (cytarabine: daunorubicin) liposome for injection
- **DRUG:** Vyxeos

## Key facts

- **NCT ID:** NCT05801835
- **Lead sponsor:** CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-08-25
- **Primary completion:** 2025-04
- **Final completion:** 2025-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05801835

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05801835, "A Bioequivalence Study of (Cytarabine: Daunorubicin) Liposome for Injection". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05801835. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*